AAMU
IBRX icon

Amundi Asset Management US’s ImmunityBio IBRX Stock Holding History

Amundi Asset Management US’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-39
Closed -$1K – 1557
2020
Q4 		$1K Hold
39
– – ﹤0.01% 1457
2020
Q3 		$0 Hold
39
– – ﹤0.01% 1625
2020
Q2 		$0 Hold
39
– – ﹤0.01% 1646
2020
Q1 		$0 Hold
39
– – ﹤0.01% 1632
2019
Q4 		$0 Hold
39
– – ﹤0.01% 1632
2019
Q3 		$0 Hold
39
– – ﹤0.01% 1662
2019
Q2 		$0 Hold
39
– – ﹤0.01% 1681
2019
Q1 		$0 Hold
39
– – ﹤0.01% 1657
2018
Q4 		$0 Hold
39
– – ﹤0.01% 1629
2018
Q3 		$0 Hold
39
– – ﹤0.01% 1627
2018
Q2 		$0 Hold
39
– – ﹤0.01% 1591
2018
Q1 		$0 Sell
39
-8,100
-100% -$35.5K ﹤0.01% 1563
2017
Q4 		$37K Buy
+8,139
New +$38.5K ﹤0.01% 1529

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Amundi Asset Management US's IBRX Position: Q1 2021 in Review

Amundi Asset Management US sold out of ImmunityBio (IBRX) in Q1 2021, closing a stake of 39 shares — an estimated $1K sold.

Amundi Asset Management US first reported a position in IBRX in Q4 2017 and held it in 13 quarters. The position peaked at $37K in Q4 2017. 126 funds tracked by Wall St. Rank hold IBRX as of Q1 2021.

  • Amundi Asset Management US reported no remaining ImmunityBio position as of Q1 2021 after selling out during the quarter.
  • Amundi Asset Management US sold 39 ImmunityBio shares in Q1 2021, an estimated $1K.
  • Amundi Asset Management US first reported a position in ImmunityBio in Q4 2017 and held it in 13 quarters.
  • Amundi Asset Management US's ImmunityBio position peaked at $37K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.